

11 September 2026

Multiple Sclerosis

Question One:

How many patients has your trust treated in the past six months (for any disease) with the following drugs:

Drug Name	Patient Numbers
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	24
Betaferon (interferon beta-1b)	>10
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	47
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	49
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	>10
Mayzent (siponimod)	13
Ocrevus (ocrelizumab)	228
Plegridy (peginterferon beta-1a)	17
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	14
Tecfidera (dimethyl fumarate)	0
Tysabri (natalizumab)	39
Tysabri (natalizumab) Pre-filled syringes only	45
Vumerity (diroximel fumarate)	35
Zeposia (ozanimod)	0
Fingolimod generic	46
Tyruko (Natalizumab Biosimilar)	0
Briumvi (ublituximab)	0
Dimethyl fumarate generic	245
Teriflunomide generic	97

11 September 2026

Question Two:

How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months? 0

Question Three:

How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)? 2893

Question Four:

Of the patients with a diagnosis of Multiple Sclerosis, how many patients have a diagnosis of:

Condition	<i>Patient Numbers</i>
RRMS – Relapse Remitting Multiple Sclerosis	1884
PPMS – Primary Progressive Multiple Sclerosis	129
SPMS – Secondary Progressive Multiple Sclerosis	414

Note: The answers to questions 3 and 4 do not add up. It is likely that the precise clinical course is not specifically documented for all cases.